Enobia, which is based in Montreal and Cambridge, Mass., focuses on development of therapies for patients with genetic metabolic bone disorders. Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs.
Enobia Pharma was acquired by Alexion Pharmaceuticals on December 28, 2011.
Join Mergr to view all 8 acquisitions of companies in 2011, including 4 acquisitions by private equity firms, and 4 by strategics.
Join Mergr to view this profile - and discover more acquisitions of companies like Enobia Pharma.
No obligation. Cancel anytime.